Sun, Sep 21, 2014, 2:59 PM EDT - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

diaDexus, Inc. Message Board

  • smelky_kid smelky_kid May 7, 2013 10:45 AM Flag

    Increased expenses---DDXS is ramping up for something!!!

    Is it possible that Glaxo already knows the outcome of Darapladib phase III study and is telling little baby Diadexus that they better be able to produce the Plac test from the millions to the multi millions or we are going to take over the operation? The only way Darapladib becomes a blockbuster drug is if the 100's of millions of potential patients are giving the PLAC test determine if they have high levels of LP-PLA2 in the first place. Diadexus is the gatekeeper to Glaxo's biggest drug launch of all time, if approved. So either Diadexus starts a major push or they get swallowed up....

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • I don't think this is a Darapladib ramp. They believe they have a legit business with or without Darapladib. Again, in their minds, they need to spread the word about Lp-pla2, and they also see the efforts starting to pay off with better insurance and government reimbursement. This is where they are saying they are spending the dollars. I hope they are right.

      Stock-wise... I wish they had posted a profit.

      • 1 Reply to sschatzi33
      • In today's presentation Brian Ward said, "the goal is to Reduce LpPLA2 levels". Kind of interesting, he doesn't normally say that… just says high levels are an indicator, not a cause. We hope it's a cause and that Darapladib can reduce it, but we don't actually know that yet.

        The future path of DDXS will be massively affected by this Darapladib trial. So, with Glaxo on the board, question #1 at each board meeting should be, HOW IS THE TRIAL GOING? It seems logical that DiaDexus management would be in the loop on this. If I was Brian, and had inside info, i would only mention anything to do with Darapladib if it were looking positive. Otherwise just talk down the trial so as to not make it a make or break factor in the share price. They have to be confident in Darapladib to keep talking about it. The day the trial results come out… oh boy!

0.520.00(-0.19%)Sep 19 3:59 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.